Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald de Wit

Showing results (111-120 of 175) with videos related to

Pageof 18
Sort By:
British Journal of Clinical Pharmacology|February 10, 2019
Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction studyBodine P S Belderbos, Koen G A M Hussaarts, Leonie J van Harten, et al.
Molecular Cancer Therapeutics|November 29, 2023
Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S TransitionStefan A J Buck, Annelies Van Hemelryk, Corrina de Ridder, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 21, 2023
A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamideStefan A J Buck, Marinda Meertens, Frederiek M F van Ooijen, et al.
Molecular Oncology|June 16, 2026
Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancerYoussra Salhi, Stavros Makrodimitris, Sandra van Wilpe, et al.
Ebiomedicine|November 8, 2021
Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancerLisanne Mout, Martin E van Royen, Corrina de Ridder, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|July 14, 2012
Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an updateAnneke Westermann, Olav Mella, Jacoba Van Der Zee, et al.
Molecular Oncology|February 19, 2022
Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancerPauline A J Mendelaar, Debbie G J Robbrecht, Maud Rijnders, et al.
European Urology|July 18, 2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD StudyCora N Sternberg, Daniel Castellano, Johann de Bono, et al.
Cancer|June 22, 2005
First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinomaAnneke M Westermann, Ellen L Jones, Baard-Christian Schem, et al.
International Journal of Cancer|March 16, 2024
Darolutamide does not interfere with OATP-mediated uptake of docetaxelStefan A J Buck, Zahra Talebi, Thomas Drabison, et al.
Pageof 18

Showing results (111-120 of 175) with videos related to

Sort By:
Pageof 18
British Journal of Clinical Pharmacology|February 10, 2019
Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction studyBodine P S Belderbos, Koen G A M Hussaarts, Leonie J van Harten, et al.
Molecular Cancer Therapeutics|November 29, 2023
Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S TransitionStefan A J Buck, Annelies Van Hemelryk, Corrina de Ridder, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 21, 2023
A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamideStefan A J Buck, Marinda Meertens, Frederiek M F van Ooijen, et al.
Molecular Oncology|June 16, 2026
Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancerYoussra Salhi, Stavros Makrodimitris, Sandra van Wilpe, et al.
Ebiomedicine|November 8, 2021
Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancerLisanne Mout, Martin E van Royen, Corrina de Ridder, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|July 14, 2012
Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an updateAnneke Westermann, Olav Mella, Jacoba Van Der Zee, et al.
Molecular Oncology|February 19, 2022
Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancerPauline A J Mendelaar, Debbie G J Robbrecht, Maud Rijnders, et al.
European Urology|July 18, 2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD StudyCora N Sternberg, Daniel Castellano, Johann de Bono, et al.
Cancer|June 22, 2005
First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinomaAnneke M Westermann, Ellen L Jones, Baard-Christian Schem, et al.
International Journal of Cancer|March 16, 2024
Darolutamide does not interfere with OATP-mediated uptake of docetaxelStefan A J Buck, Zahra Talebi, Thomas Drabison, et al.
Pageof 18